Product Launch (Blog)

Jul, 11 2024

Robust Growth and Strategic Advancements Define the Global Bladder Disorders Market

The global bladder disorders market is experiencing significant growth, driven by an aging population, increasing prevalence of bladder-related conditions such as overactive bladder, cystitis, and bladder cancer, and rising awareness about bladder health. Technological advancements in diagnostic techniques and treatment options, including minimally invasive surgeries, innovative drug therapies, and novel medical devices, are also contributing to market expansion. Additionally, increased healthcare expenditure and supportive government initiatives for research and development are fueling market growth. However, high treatment costs and potential side effects associated with certain therapies may pose challenges. Overall, the market is expected to witness robust growth, with key players focusing on strategic collaborations and product innovations to strengthen their market position.                          

The Global Bladder Disorders Market size is projected to reach USD 22,342.48  million by 2029, with a CAGR of 11.4% during the forecast period of 2024 to 2031.  

To know more, visit

Below are the Top Five Bladder Disorders Companies with a Significant Market Share:




Product Portfolio

Sales Geographical Coverage



Merck & Co., Inc.

Merck focuses on the development and commercialization of pharmaceutical products for various bladder-related conditions, including overactive bladder and bladder cancer. Merck's commitment to research and development is evident in its extensive pipeline of products aimed at improving patient outcomes and advancing bladder health. The company's strategic initiatives include collaborations and acquisitions to enhance its portfolio and expand its market presence. 


North America, Middle East and Africa, Europe, South America, Asia-Pacific

In August 2021, Merck announced the keytruda, approved for treatment of patients With Locally Advanced or Metastatic Urothelial Carcinoma. This approval received by the company has strengthened the bladder disorder market portfolio leading to increased sales and demand in the market.


Astellas Pharma Inc.

Astellas is recognized for its significant contributions, particularly in the treatment of overactive bladder and other urinary conditions. The company's flagship product, mirabegron (Myrbetriq/BETMIGA), is a leading therapy for overactive bladder, offering a novel mechanism of action as a beta-3 adrenergic agonist. Astellas' commitment to research and development is evident in its continuous efforts to innovate and expand its urology portfolio.


  • Betanis/Myrbetriq/BETMIGA

North America, Middle East and Africa, Europe, South America, Asia-Pacific

In March 2021, Astellas Pharma Inc. revealed that the U.S FDA gives approval Myrbetriq® (mirabegron extended-release tablets) for the treatment of NDO in pediatric patients aged three years and older who weigh 35 kg or more, and Myrbetriq® Granules (mirabegron for extended-release oral suspension) for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged three years and older.


Bristol-Myers Squibb Company

BMS is particularly known for its advancements in oncology, including treatments for bladder cancer. The company's robust research and development efforts are focused on immuno-oncology and precision medicine, aiming to provide effective therapies for bladder cancer patients. BMS leverages its expertise in biologics and small molecule drugs to offer a comprehensive range of treatment options. Strategic partnerships and acquisitions further bolster its capabilities in addressing bladder disorders.        

  • Opdivo® (nivolumab)

North America, Middle East and Africa, Europe, South America, Asia-Pacific

In March 2022, Bristol Myers Squibb announced the receiving approval for Opdivo (nivolumab) from European Commission for the adjuvant treatment of adults with muscle-invasive urothelial carcinoma with tumor cell PD-L1 expression ≥1% who are at a high risk of recurrence. This approval will rise the global presence of the drug for the urothelial carcinoma as well as the company.


Boston Scientific Corporation


 Boston Scientific offers innovative solutions for managing conditions like overactive bladder, urinary incontinence, and bladder cancer. The company's product portfolio includes minimally invasive therapies, such as the InterStim™ system for bladder control and endoscopic tools for bladder cancer diagnosis and treatment. Boston Scientific's focus on research and development drives the continuous improvement of its medical devices, aiming to enhance patient quality of life. Strategic collaborations and market expansion efforts support its growth.      

  • AMS 800™ Artificial Urinary Sphincter
  • AdVance™ XP Male Sling System
  • Coaptite Urethral Bulking Injection
  • Solyx™ SIS System

North America, Middle East and Africa, Europe, South America, Asia-Pacific


In January 2024, Boston Scientific Corporation announced that it has entered into a definitive agreement to acquire Axonics, Inc., a publicly traded medical technology company specializing in the development and commercialization of innovative devices for treating urinary and bowel dysfunction.


Viatris Inc.

Viatris provides a wide range of pharmaceutical products, including treatments for bladder disorders. The company's extensive portfolio features generic and branded medications for conditions such as overactive bladder and urinary tract infections. Viatris is committed to increasing access to affordable and high-quality healthcare solutions worldwide. The company invests in research and development to bring innovative therapies to the market.

  • Detrol® LA
  • Oxybutynin

North America, Middle East and Africa, Europe, South America, Asia-Pacific



The global bladder disorders market is poised for significant growth, driven by an aging population, rising prevalence of bladder-related conditions, and advancements in diagnostic and treatment technologies. Key players are at the forefront of this market, leveraging their extensive research and development capabilities to introduce innovative solutions. Their strategic initiatives, including collaborations, acquisitions, and a focus on expanding their product portfolios, are critical to addressing the diverse needs of patients with bladder disorders. Despite challenges like high treatment costs and potential side effects, the market's robust growth prospects are underscored by ongoing advancements and a strong commitment to improving patient outcomes.

Client Testimonials